Business Context and Reporting Period
This Form 8-K reports on the 2019 Annual Meeting of Stockholders held by Leap Therapeutics, Inc. (noting a discrepancy with the provided metadata name "Cypherpunk Technologies Inc.") on June 11, 2019. The company is incorporated in Delaware, trades on the Nasdaq Global Market under the symbol LPTX, and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders with the following results:
- Election of Directors: William Li and Thomas Dietz were elected as Class II directors to serve until the 2022 annual meeting.
- William Li: 9,786,611 votes for; 564,611 votes withheld.
- Thomas Dietz: 9,825,064 votes for; 528,158 votes withheld.
- Ratification of Auditors: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2019, was ratified.
- Votes For: 18,890,995
- Votes Against: 1,290,841
- Votes Abstaining: 10,729
- Equity Plan Amendment: The First Amendment to the 2016 Equity Incentive Plan was approved, increasing the number of shares reserved for issuance by 3,000,000 shares.
- Votes For: 9,260,063
- Votes Against: 1,059,535
- Votes Abstaining: 33,624
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the correct registrant name is Leap Therapeutics, Inc. (LPTX), as the metadata provided a different company name.
- Confirm the impact of the 3,000,000 share increase in the 2016 Equity Incentive Plan on potential dilution.
- Note the significant number of votes against the auditor ratification (approx. 6.4% of total votes cast) and the votes withheld for director nominees (approx. 5.4% and 5.1% respectively).
- Review the company's most recent 10-K or 10-Q for financial metrics, as this 8-K contains no financial data.